Myomo® Announces New Distribution Agreement
for Australia / New Zealand

Neuro Muscular Orthotics to OfferMyoPro®
Across a Huge New Geography

May 01, 2019 08:00 AM Eastern Daylight Time

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a wearable
medical robotics company that offers increased functionality for those
suffering from neurological disorders and upper limb paralysis, today
announced that it has signed an agreement with NeuroMuscular Orthotics
Pty Ltd (NMO) with the goal of offering MyoPro across Australia and New
Zealand.

NMO is the leading Australian specialist in facilitating optimal
orthotic care of individuals with long term functional impairment as a
result of neurological and orthopedic pathologies. The company achieves
this through direct clinical service provision to its own clients in
Melbourne and Sydney, and through its sister clinic Interface Orthotics
in Perth. In addition, NeuroMuscular Orthotics expands its reach
throughout Australia and New Zealand by offering distribution, central
fabrication and education to certified orthotist/prosthetists.

Darren Pereira, NMO Director, explains, “NeuroMuscular Orthotics is
excited to be partnering with the passionate and innovative team at
Myomo to bring the MyoPro powered orthosis to Australia and New Zealand.
As the only product of its kind, the MyoPro will unlock new
possibilities for many Australians and New Zealanders with upper limb
impairment, aiding in their social and economic participation, helping
them to achieve their goals and live an ordinary life.”

Paul R. Gudonis, Chairman and CEO of Myomo, said, “NMO is one of the
strongest technical orthotics providers in one of the strongest
economies in the Pacific region. It is an honor to call them a partner,
and we look forward to offering MyoPro to the tens of thousands of
Australians suffering a paralyzed arm from stroke, nerve injury of other
neuromuscular disease.”

About Myomo

Myomo, Inc. is a wearable medical robotics company that offers expanded
mobility for those suffering from neurological disorders and upper limb
paralysis. Myomo develops and markets the MyoPro product line. MyoPro is
a powered upper limb orthosis designed to support the arm and restore
function to the weakened or paralyzed arms of patients suffering from
CVA stroke, brachial plexus injury, traumatic brain or spinal cord
injury, ALS or other neuromuscular disease or injury. It is currently
the only marketed device that, sensing a patient’s own EMG signals
through non-invasive sensors on the arm, can restore an individual’s
ability to perform activities of daily living, including feeding
themselves, carrying objects and doing household tasks. Many are able to
return to work, live independently and reduce their cost of care. Myomo
is headquartered in Cambridge, Massachusetts, with sales and clinical
professionals across the U.S. and representatives internationally. For
more information, please visit www.myomo.com.

Forward Looking Statements

This press release contains forward-looking statements regarding the
Company's future business expectations which are subject to the safe
harbor provisions of the Private Securities Litigation Reform Act of
1995. These forward-looking statements include, but are not limited to,
our collaboration with NeuroMuscular Orthotics and plans for offering
our MyoPro product in Australia and New Zealand. These forward-looking
statements are only predictions and may differ materially from actual
results due to a variety of factors. Our actual results could differ
materially from those anticipated in these forward looking statements
for many reasons, including, without limitation, risks related to
regulatory approval and market acceptance of our products, our ability
to secure and maintain reimbursement for our products, our ability to
obtain additional funding to sustain and grow our business, and the
other risk factors contained in our filings made with the Securities and
Exchange Commission. More information about factors that potentially
could affect Myomo's business and financial results is included in
Myomo's filings with the Securities and Exchange Commission. The Company
cautions readers not to place undue reliance on any such forward-looking
statements, which speak only as of the date made. The Company disclaims
any obligation subsequently to revise any forward-looking statements to
reflect events or circumstances after the date of such statements or to
reflect the occurrence of anticipated or unanticipated events.